XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets
 6 Months Ended
Jul. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
December 31, 2022Purchase accounting adjustments Currency translation
adjustments		July 1, 2023
CSCA(1)
$2,044.4 $35.2 $0.4 $2,080.0 
CSCI(2)
1,446.0 45.4 26.6 1,518.0 
Total goodwill$3,490.4 $80.6 $27.0 $3,598.0 
(1) We had accumulated goodwill impairments of $6.1 million as of July 1, 2023 and December 31, 2022.
(2) We had accumulated goodwill impairments of $878.4 million as of July 1, 2023 and December 31, 2022.
Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):
 July 1, 2023December 31, 2022
 GrossAccumulated
Amortization		GrossAccumulated
Amortization
Indefinite-lived intangibles:(1)
Trademarks, trade names, and brands$3.4 $— $3.2 $— 
In-process research and development56.4 — 55.4 — 
Total indefinite-lived intangibles$59.8 $— $58.6 $— 
Definite-lived intangibles:
Distribution and license agreements and supply agreements$95.6 $60.7 $94.9 $58.1 
Developed product technology, formulations, and product rights476.5 225.1 484.8 211.8 
Customer relationships and distribution networks1,854.0 1,043.2 1,825.1 965.9 
Trademarks, trade names, and brands2,476.7 543.0 2,542.2 481.0 
Non-compete agreements2.1 2.1 2.0 2.0 
Total definite-lived intangibles$4,904.9 $1,874.1 $4,949.0 $1,718.8 
Total intangible assets$4,964.7 $1,874.1 $5,007.6 $1,718.8 
(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

On July 13, 2023, we announced that we received final approval from the U.S. Food and Drug Administration for Opill®, a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages. As a result, the Opill® in-process research and development (“IPR&D”), acquired through the 2022 acquisition of HRA Pharma, will be reclassified from indefinite-lived to finite-lived intangible asset in the third quarter.

We recorded amortization expense of $69.3 million and $134.7 million for the three and six months ended July 1, 2023, respectively and $62.4 million and $110.9 million for the three and six months ended July 2, 2022, respectively.